Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EX10
|
| gptkbp:brand |
gptkb:Vitrakvi
|
| gptkbp:CASNumber |
1223403-58-4
|
| gptkbp:developer |
gptkb:Bayer
gptkb:Loxo_Oncology |
| gptkbp:indication |
solid tumors with NTRK gene fusion
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits tropomyosin receptor kinases (TRK)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea vomiting dizziness fatigue increased liver enzymes |
| gptkbp:target |
gptkb:TRK_fusion_proteins
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Larotrectinib
|